SI3542817T1 - Virus humane imunske pomanjkljivosti(HIV) - nevtralizirajoča protitelesa - Google Patents

Virus humane imunske pomanjkljivosti(HIV) - nevtralizirajoča protitelesa

Info

Publication number
SI3542817T1
SI3542817T1 SI201032112T SI201032112T SI3542817T1 SI 3542817 T1 SI3542817 T1 SI 3542817T1 SI 201032112 T SI201032112 T SI 201032112T SI 201032112 T SI201032112 T SI 201032112T SI 3542817 T1 SI3542817 T1 SI 3542817T1
Authority
SI
Slovenia
Prior art keywords
hiv
immunodeficiency virus
human immunodeficiency
neutralizing antibodies
neutralizing
Prior art date
Application number
SI201032112T
Other languages
English (en)
Inventor
Steven Frey
Melissa Danielle De Jean De St. Marcel Simek-Lemos
Po-Ying Chan-Hui
Jennifer Mitcham
Ole Olsen
Matthew Moyle
Sanjay K. Phogat
Dennis Burton
Laura Marjorie Walker
Wayne Koff
Stephen Kaminsky
Original Assignee
International Aids Vaccine Initiative
Theraclone Sciences, Inc.
The Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by International Aids Vaccine Initiative, Theraclone Sciences, Inc., The Scripps Research Institute filed Critical International Aids Vaccine Initiative
Publication of SI3542817T1 publication Critical patent/SI3542817T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI201032112T 2009-03-17 2010-03-17 Virus humane imunske pomanjkljivosti(HIV) - nevtralizirajoča protitelesa SI3542817T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16101009P 2009-03-17 2009-03-17
US16582909P 2009-04-01 2009-04-01
US22473909P 2009-07-10 2009-07-10
US28566409P 2009-12-11 2009-12-11
EP18207707.3A EP3542817B1 (en) 2009-03-17 2010-03-17 Human immunodeficiency virus (hiv)-neutralizing antibodies

Publications (1)

Publication Number Publication Date
SI3542817T1 true SI3542817T1 (sl) 2022-09-30

Family

ID=42668183

Family Applications (4)

Application Number Title Priority Date Filing Date
SI201032049T SI3260136T1 (sl) 2009-03-17 2010-03-01 Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
SI201032112T SI3542817T1 (sl) 2009-03-17 2010-03-17 Virus humane imunske pomanjkljivosti(HIV) - nevtralizirajoča protitelesa
SI201031616T SI2408476T1 (sl) 2009-03-17 2010-03-17 Humani imunodificientni virus (hiv)-nevtralizirajoča protitelesa
SI201032062T SI3323427T1 (sl) 2009-03-17 2010-03-17 Protitelesa, ki nevtralizirajo virus humane imunske pomanjkljivosti (HIV)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI201032049T SI3260136T1 (sl) 2009-03-17 2010-03-01 Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa

Family Applications After (2)

Application Number Title Priority Date Filing Date
SI201031616T SI2408476T1 (sl) 2009-03-17 2010-03-17 Humani imunodificientni virus (hiv)-nevtralizirajoča protitelesa
SI201032062T SI3323427T1 (sl) 2009-03-17 2010-03-17 Protitelesa, ki nevtralizirajo virus humane imunske pomanjkljivosti (HIV)

Country Status (15)

Country Link
US (7) US9051362B2 (sl)
EP (5) EP2408476B1 (sl)
AU (5) AU2010226668B2 (sl)
CA (2) CA2755821C (sl)
CY (1) CY1121323T1 (sl)
DK (1) DK2408476T3 (sl)
ES (4) ES2848555T3 (sl)
HR (1) HRP20180027T1 (sl)
HU (1) HUE036031T2 (sl)
LT (1) LT2408476T (sl)
NO (1) NO2408476T3 (sl)
PL (4) PL3542817T3 (sl)
PT (4) PT2408476T (sl)
SI (4) SI3260136T1 (sl)
WO (1) WO2010107939A2 (sl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2623794T3 (es) 2008-12-09 2017-07-12 Gilead Sciences, Inc. Intermedios para la preparación de moduladores de receptores tipo toll
WO2011092593A2 (en) * 2010-01-20 2011-08-04 Institute For Research In Biomedicine Hiv-1 neutralizing antibodies and uses thereof
WO2011109511A2 (en) * 2010-03-02 2011-09-09 International Aids Vaccine Initiative Novel hiv-1 envelope glycoprotein
PT3556396T (pt) * 2010-08-31 2022-07-04 Scripps Research Inst Anticorpos neutralizantes do vírus da imunodeficiência humana (vih)
WO2012040562A2 (en) 2010-09-24 2012-03-29 International Aids Vaccine Initiative Novel hiv-1 broadly neutralizing antibodies
EP2492279A1 (en) 2011-02-25 2012-08-29 Laboratorios Del. Dr. Esteve, S.A. Rapid immunogen selection method using lentiviral display
US10040826B2 (en) 2011-07-05 2018-08-07 Duke University Human immunodeficiency virus type 1 (HIV-1) N-terminal deleted GP120 immunogens
US8791108B2 (en) * 2011-08-18 2014-07-29 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US20140348865A1 (en) 2011-09-12 2014-11-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Ser. Immunogens based on an hiv-1 v1v2 site-of-vulnerability
EP2763699A4 (en) * 2011-10-03 2015-05-20 Univ Duke VACCINE
US9988424B2 (en) 2011-12-05 2018-06-05 Duke University Immunogens comprising human immunodeficiency virus V1/V2 polypeptides
CN108676091B (zh) 2011-12-08 2022-04-01 美国政府(由卫生和人类服务部的部长所代表) Hiv-1的中和抗体及其用途
US20150044137A1 (en) * 2012-03-23 2015-02-12 The United States of America, as represented by the Secretary, Dep. of Health Care Human Services Neutralizing antibodies to hiv-1 and their use
EP2698377A1 (en) 2012-08-17 2014-02-19 Laboratorios Del. Dr. Esteve, S.A. Enhanced rapid immunogen selection method for HIV gp120 variants
WO2014134547A1 (en) * 2013-02-28 2014-09-04 Therabiol, Inc. Hiv antigens and antibodies
US20160130328A1 (en) * 2013-06-17 2016-05-12 Emory University Pathogen Binding Agents Conjugated to Radioisotopes and Uses in Imaging and Therapeutic Applications
WO2015048517A1 (en) * 2013-09-28 2015-04-02 Duke University Escape mutants
WO2015127108A1 (en) * 2014-02-19 2015-08-27 Duke University Trimeric hiv-1 envelopes compositions and uses thereof
US10093720B2 (en) * 2014-06-11 2018-10-09 International Aids Vaccine Initiative Broadly neutralizing antibody and uses thereof
PL3166607T3 (pl) 2014-07-11 2023-02-20 Gilead Sciences, Inc. Modulatory receptorów toll-podobnych do leczenia hiv
CN106715431A (zh) 2014-09-16 2017-05-24 吉利德科学公司 Toll样受体调节剂的固体形式
WO2016054023A1 (en) * 2014-09-29 2016-04-07 Duke University Hiv-1 antibodies and uses thereof (adcc and bispecific abs)
MA42818A (fr) 2015-09-15 2018-07-25 Gilead Sciences Inc Modulateurs de récepteurs de type toll pour le traitement du vih
BR112018005931A2 (pt) 2015-09-24 2018-10-09 Abvitro Llc composições de anticorpo para hiv e métodos de uso
WO2017106346A2 (en) 2015-12-15 2017-06-22 Gilead Sciences, Inc. Human immunodeficiency virus neutralizing antibodies
CN107022027B (zh) * 2016-02-02 2022-03-08 中国疾病预防控制中心性病艾滋病预防控制中心 Hiv-1广谱中和抗体及其用途
CN107033241B (zh) * 2016-02-03 2022-03-08 中国疾病预防控制中心性病艾滋病预防控制中心 Hiv-1广谱中和抗体及其用途
EP3642229A1 (en) 2017-06-21 2020-04-29 Gilead Sciences, Inc. Multispecific antibodies that target hiv gp120 and cd3
EP3641806A4 (en) * 2017-06-22 2021-06-23 University of Maryland, Baltimore BROAD NEUTRALIZING ANTIBODIES AGAINST HIV
JP7126573B2 (ja) 2018-07-03 2022-08-26 ギリアード サイエンシーズ， インコーポレイテッド ＨＩＶ ｇｐ１２０を標的化する抗体および使用方法
WO2020082045A1 (en) * 2018-10-19 2020-04-23 University Of Maryland, College Park Multispecfic anti-hiv antibodies
CA3145791A1 (en) 2019-07-16 2021-01-21 Gilead Sciences, Inc. Hiv vaccines and methods of making and using
US20230134571A1 (en) * 2019-10-29 2023-05-04 International Aids Vaccine Initiative Engineered antibodies to hiv env
US20210277093A1 (en) * 2020-03-09 2021-09-09 Adma Biologics, Inc. Immunotherapeutic compositions and methods of production for coronavirus
JP2023539196A (ja) 2020-08-25 2023-09-13 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖを標的とする多重特異性抗原結合分子及び使用方法
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
WO2022162009A1 (en) 2021-01-26 2022-08-04 Eth Zurich Method for rapid identification of cross-reactive and/or rare antibodies
WO2022161597A1 (en) * 2021-01-26 2022-08-04 Eth Zurich Method for rapid identification of cross-reactive and/or rare antibodies
WO2022225875A1 (en) * 2021-04-19 2022-10-27 The Wistar Institute Of Anatomy And Biology Sialydase linked hiv antibodies and methods of use
WO2024015741A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. Hiv immunogenic polypeptides and vaccines and uses thereof

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DK0479909T3 (da) 1989-06-29 1997-04-07 Medarex Inc Bispecifikke reagenser til AIDS-behandling
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
WO1992000373A1 (en) 1990-06-29 1992-01-09 Biosource Genetics Corporation Melanin production by transformed microorganisms
EP0542810A1 (en) 1990-08-02 1993-05-26 B.R. Centre Limited Methods for the production of proteins with a desired function
DK0546073T3 (da) 1990-08-29 1998-02-02 Genpharm Int Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ES2241710T3 (es) 1991-11-25 2005-11-01 Enzon, Inc. Procedimiento para producir proteinas multivalentes de union a antigeno.
EP0625200B1 (en) 1992-02-06 2005-05-11 Chiron Corporation Biosynthetic binding protein for cancer marker
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
ATE196606T1 (de) 1992-11-13 2000-10-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma
ES2162863T3 (es) 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
EP1241264A1 (en) 1994-12-02 2002-09-18 Chiron Corporation Monoclonal antibodies to colon cancer antigen
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US6815201B2 (en) 1997-09-08 2004-11-09 The Public Health Research Institute Of The City Of New York, Inc. HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies
US6824780B1 (en) 1999-10-29 2004-11-30 Genentech, Inc. Anti-tumor antibody compositions and methods of use
JP4773947B2 (ja) 2003-01-09 2011-09-14 マクロジェニクス，インコーポレーテッド 細菌細胞及び哺乳動物細胞における抗体発現のための二重発現ベクター系
EP1597280B2 (en) 2003-02-26 2016-08-24 Institute for Research in Biomedicine Monoclonal antibody production by ebv transformation of b cells
AU2005302416A1 (en) * 2004-10-29 2006-05-11 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Broadly cross-reactive HIV-1 neutralizing human monoclonal antibodies
PT3556396T (pt) * 2010-08-31 2022-07-04 Scripps Research Inst Anticorpos neutralizantes do vírus da imunodeficiência humana (vih)

Also Published As

Publication number Publication date
ES2848555T3 (es) 2021-08-10
PL3542817T3 (pl) 2022-09-19
US20150218257A1 (en) 2015-08-06
EP4085925A1 (en) 2022-11-09
SI3260136T1 (sl) 2021-05-31
US10407493B2 (en) 2019-09-10
US20210040186A1 (en) 2021-02-11
AU2020210242B2 (en) 2023-04-06
CY1121323T1 (el) 2020-05-29
US20190169273A1 (en) 2019-06-06
AU2017264985B2 (en) 2020-05-07
EP2408476B1 (en) 2017-10-18
PL3260136T3 (pl) 2021-10-18
HUE036031T2 (hu) 2018-06-28
PL2408476T3 (pl) 2018-05-30
SI3323427T1 (sl) 2021-07-30
PT2408476T (pt) 2018-01-19
EP3260136B1 (en) 2020-11-25
AU2010226668B2 (en) 2015-07-16
US20190338017A1 (en) 2019-11-07
US9051362B2 (en) 2015-06-09
NO2408476T3 (sl) 2018-03-17
US10865234B2 (en) 2020-12-15
WO2010107939A3 (en) 2011-05-26
AU2017264985A1 (en) 2017-12-07
PL3323427T3 (pl) 2021-10-11
DK2408476T3 (en) 2018-01-22
PT3260136T (pt) 2021-02-12
AU2010226668A1 (en) 2011-10-06
ES2656234T3 (es) 2018-02-26
LT2408476T (lt) 2018-03-26
CA2755821C (en) 2017-11-14
US11584789B2 (en) 2023-02-21
EP2408476A2 (en) 2012-01-25
PT3542817T (pt) 2022-07-05
CA2980883C (en) 2020-12-29
AU2015234345C1 (en) 2017-12-21
EP3260136A1 (en) 2017-12-27
AU2023204017A1 (en) 2023-07-13
EP3323427B1 (en) 2021-01-13
US20110044994A1 (en) 2011-02-24
PT3323427T (pt) 2021-03-03
AU2020210242A1 (en) 2020-08-20
AU2015234345A1 (en) 2015-11-05
EP3542817A1 (en) 2019-09-25
US20190031742A1 (en) 2019-01-31
ES2916404T3 (es) 2022-06-30
CA2755821A1 (en) 2010-09-23
US20230295278A1 (en) 2023-09-21
EP3542817B1 (en) 2022-05-11
US10239934B2 (en) 2019-03-26
SI2408476T1 (sl) 2018-04-30
WO2010107939A2 (en) 2010-09-23
ES2848203T3 (es) 2021-08-05
EP3323427A1 (en) 2018-05-23
US9920111B2 (en) 2018-03-20
AU2015234345B2 (en) 2017-09-21
HRP20180027T1 (hr) 2018-04-20
CA2980883A1 (en) 2010-09-23

Similar Documents

Publication Publication Date Title
PL3542817T3 (pl) Przeciwciała neutralizujące ludzki wirus niedoboru odporności (hiv)
AU2016202543A1 (en) Human immunodeficiency virus (hiv)-neutralizing antibodies
EP2611465A4 (en) NEUTRALIZING ANTI-VIRUS ANTIBODIES FOR HUMAN IMMUNODEFICIENCY (HIV)
HK1212935A1 (zh) 廣譜中和抗 抗體
AP2011005944A0 (en) Inhibitors of human immunodeficiency virus replication.
EP2380976A4 (en) HUMAN ANTIBODY AGAINST HUMAN FLUX VIRUS
PT3494972T (pt) Combinações de dolutegravir e lamivudina para o tratamento de infeção pelo hiv
DK3329772T3 (da) Dobbeltvektor til inhibering af human immundefektvirus
ZA201202116B (en) Neutralizing antibodies to hiv-1 and their use
EP2618843A4 (en) NEW ANTIBODIES WITH EXCESSIVE HIV-1 NEUTRALIZATION
EP2542703A4 (en) NEW HIV-1 ENVELOPE GLYCOPROTEIN
IL222228A0 (en) Hiv vaccine
ZA201002445B (en) Hiv preventive vaccine based on hiv specific antibodies
IL212311A0 (en) Immunoenhancer-linked oligomeric hiv vaccines
EP2571523A4 (en) REACTIVATION OF THE HUMAN IMMUNODEFICIENCY VIRUS IN THE LATENT STATE
EP2635300A4 (en) DOCK-AND-LOCK (DNL) CONSTRUCTS FOR THERAPY AGAINST HUMAN IMMUNE WEAKAGE VIRUS (HIV)
GB0912950D0 (en) Virus
EP2542252A4 (en) HIV-1 CASE-BASED FRAGMENTS
ZA201302639B (en) Antibodies for the treatment of hiv
EP2643460A4 (en) METHOD, COMPOSITIONS AND KITS FOR IDENTIFYING HUMAN IMMUNE FIZIENZVIRUS (HIV)
ZA201105357B (en) Splitting gp41
GB0901056D0 (en) Virus
HK1177692A1 (zh) 新的流感病毒
AP3595A (en) Novel gp41 antigens
GB201005057D0 (en) HIV-1 ENV-deactivating alpha-bodies